Taysha Gene Therapies Inc (TSHA) financials
Taysha Gene Therapies revenue and earnings by year
Taysha Gene Therapies's revenue was $9.77 million in the fiscal year to December 31, 2025, up 17.3% from the year before. Net income was -$109 million, -1115.3% of revenue. Since the fiscal year to December 31, 2022, revenue has grown 57.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 10 | 8 | 15 | 3 |
| Revenue growth | 17.3% | -46.1% | 517.5% | — |
| Operating income | -110 | -91 | -72 | -162 |
| Operating margin | -1130.6% | -1097.6% | -468.8% | -6492.7% |
| Net income | -109 | -89 | -112 | -166 |
| Net margin | -1115.3% | -1071.6% | -722.1% | -6635.3% |
| Diluted EPS | -$0.34 | -$0.36 | -$0.96 | -$3.78 |
| Free cash flow | -94 | -82 | -77 | -109 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TSHA in Markets.
See also: TSHA returns
No forecast, no recommendation. This page describes Taysha Gene Therapies Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.